ArticleScientific reports2021
Disease progression modelling from preclinical Alzheimer's disease (AD) to AD dementia.
Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06868030 (Efficacy and Safety of Conventional Symptomatic Drugs Combined with Lencanizumab in the Treatment of Early Alzheimer's Disease), which is not on this map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Efficacy and Safety of Conventional Symptomatic Drugs Combined with Lencanizumab in the Treatment of Early Alzheimer's Disease: a Multicenter, Prospective, Observational Study
Who cites it
23 citing papers in PubMed, 36 citations in OpenAlex.
- AI-enabled digital phenotyping for Alzheimer's disease: a review of multimodal sensor integration and symptom trajectories.Alzheimer's research & therapy · 2026Review
- From genes to trajectories: mapping genetic influences on Huntington's disease progression.Bioinformatics (Oxford, England) · 2026Article
- Lecanemab treatment for mild alzheimer's disease with high risk of cerebral hemorrhage: a case report.BMC neurology · 2026Article
- Assessing the accuracy of survival machine learning and traditional statistical models for Alzheimer's disease prediction over time: a study on the ADNI cohort.BMC medical research methodology · 2025Article
- A preliminary economic evaluation of a potential program for the primary prevention of Alzheimer's disease.The journal of prevention of Alzheimer's disease · 2025Article
- Trajectories of plasma biomarkers, amyloid-beta burden and cognitive decline in Alzheimer's disease: A Longitudinal ADNI Study.medRxiv : the preprint server for health sciences · 2025Article
- Compensatory retinal blood flow enhancement in cognitively normal ApoE ε4 carriers.Scientific reports · 2025Article
- Tau PET positivity predicts clinically relevant cognitive decline driven by Alzheimer's disease compared to comorbid cases; proof of concept in the ADNI study.Molecular psychiatry · 2025Article
- Predicting Alzheimer's disease subtypes and understanding their molecular characteristics in living patients with transcriptomic trajectory profiling.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Gut dysbiosis as a potential driver of Parkinson's and Alzheimer's disease pathogenesis.Frontiers in neuroscience · 2025Review
- Regression Trees With Fused Leaves.Statistics in medicine · 2024Article
- Ethnic differences in the prevalence of amyloid positivity and cognitive trajectories.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Alzheimer's disease: a review on the current trends of the effective diagnosis and therapeutics.Frontiers in aging neuroscience · 2024Review
- Estimating Dementia Onset: AT(N) Profiles and Predictive Modeling in Mild Cognitive Impairment Patients.Current Alzheimer research · 2024Article
- A Systematic Review of Clinical Practice Guidelines for Alzheimer's Disease and Strategies for Future Advancements.Neurology and therapy · 2023Article
- Modeling Alzheimer's disease progression utilizing clinical trial and ADNI data to predict longitudinal trajectory of CDR-SB.CPT: pharmacometrics & systems pharmacology · 2023Observational
- Article
- Association of biological sex with clinical outcomes and biomarkers of Alzheimer's disease in adults with Down syndrome.Brain communications · 2023Article
- Biomarkers for the Diagnosis of Alzheimer's Disease in Clinical Practice: The Role of CSF Biomarkers during the Evolution of Diagnostic Criteria.International journal of molecular sciences · 2022Review
- Distinctive Temporal Trajectories of Alzheimer's Disease Biomarkers According to Sex andFrontiers in aging neuroscience · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 11 institutions in 3 countries.
Funding
Abstract
To characterize the course of Alzheimer's disease (AD) over a longer time interval, we aimed to construct a disease course model for the entire span of the disease using two separate cohorts ranging from preclinical AD to AD dementia. We modelled the progression course of 436 patients with AD continuum and investigated the effects of apolipoprotein E ε4 (APOE ε4) and sex on disease progression. To develop a model of progression from preclinical AD to AD dementia, we estimated Alzheimer's Disease Assessment Scale-Cognitive Subscale 13 (ADAS-cog 13) scores. When calculated as the median of ADAS-cog 13 scores for each cohort, the estimated time from preclinical AD to MCI due to AD was 7.8 years and preclinical AD to AD dementia was 15.2 years. ADAS-cog 13 scores deteriorated most rapidly in women APOE ε4 carriers and most slowly in men APOE ε4 non-carriers (p < 0.001). Our results suggest that disease progression modelling from preclinical AD to AD dementia may help clinicians to estimate where patients are in the disease course and provide information on variation in the disease course by sex and APOE ε4 status.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.